Uwe Schonbeck

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Soluble CD40L and cardiovascular risk in women
    U Schonbeck
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 104:2266-8. 2001
  2. ncbi T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm
    Uwe Schonbeck
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 161:499-506. 2002
  3. ncbi Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells
    Uwe Schonbeck
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 106:2888-93. 2002
  4. ncbi CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1
    Andreas Zirlik
    Donald W Reynolds Center, Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 115:1571-80. 2007
  5. ncbi TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells
    Andreas Zirlik
    Donald W Reynolds Cardiovascular Research Center, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 27:1101-7. 2007
  6. ncbi Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: possible role for a feedback loop in endothelial cells
    Alexandra Krettek
    Brigham and Womens Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, MA 02115, USA
    Am J Pathol 165:1571-81. 2004
  7. ncbi Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study
    Andreas Zirlik
    Donald W Reynolds Centers of the Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arterioscler Thromb Vasc Biol 27:2043-9. 2007
  8. ncbi Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
    Uwe Schonbeck
    Leducq Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Circulation 109:II18-26. 2004
  9. ncbi Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones
    Nerea Varo
    Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Ave, Boston, Mass 02115, USA
    Circulation 107:2664-9. 2003
  10. ncbi Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells
    Udo Bavendiek
    Donald W Reynolds Cardiovascular Clinical Research Center, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass02115, USA
    Arterioscler Thromb Vasc Biol 25:1244-9. 2005

Collaborators

Detail Information

Publications13

  1. ncbi Soluble CD40L and cardiovascular risk in women
    U Schonbeck
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Circulation 104:2266-8. 2001
    ..It is unknown, however, whether elevations of circulating sCD40L precede the onset of acute cardiovascular symptoms...
  2. ncbi T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm
    Uwe Schonbeck
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 161:499-506. 2002
    ..These findings suggest that the functional repertoire of T cells differs in stenotic and aneurysmal lesions, and provide a novel framework for understanding the mechanisms of these diametrically opposite expressions of atherosclerosis...
  3. ncbi Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells
    Uwe Schonbeck
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 106:2888-93. 2002
    ....
  4. ncbi CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1
    Andreas Zirlik
    Donald W Reynolds Center, Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 115:1571-80. 2007
    ..The present study aimed to characterize the contribution of CD40 signaling to atherogenesis...
  5. ncbi TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells
    Andreas Zirlik
    Donald W Reynolds Cardiovascular Research Center, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 27:1101-7. 2007
    ..This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis...
  6. ncbi Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: possible role for a feedback loop in endothelial cells
    Alexandra Krettek
    Brigham and Womens Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, MA 02115, USA
    Am J Pathol 165:1571-81. 2004
    ....
  7. ncbi Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study
    Andreas Zirlik
    Donald W Reynolds Centers of the Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arterioscler Thromb Vasc Biol 27:2043-9. 2007
    ..Although IL-18 promotes atherogenesis in animal studies and predicts cardiovascular risk in humans, it is unknown whether elevated IL-18 levels are associated with coronary atherosclerosis in the general population...
  8. ncbi Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
    Uwe Schonbeck
    Leducq Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Circulation 109:II18-26. 2004
    ..This overview addresses the controversy by reviewing in vitro and in vivo evidence regarding statins as antiinflammatory agents...
  9. ncbi Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones
    Nerea Varo
    Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Ave, Boston, Mass 02115, USA
    Circulation 107:2664-9. 2003
    ..This study therefore evaluated the hypothesis that diabetic patients have elevated plasma levels of soluble CD40L (sCD40L) and that treatment with the insulin-sensitizing thiazolidinediones lowers this index of inflammation...
  10. ncbi Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells
    Udo Bavendiek
    Donald W Reynolds Cardiovascular Clinical Research Center, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass02115, USA
    Arterioscler Thromb Vasc Biol 25:1244-9. 2005
    ....
  11. ncbi Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1
    Udo Bavendiek
    Leducq Center for Cardiovascular Research, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:25032-9. 2002
    ....
  12. ncbi Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis
    Norbert Gerdes
    Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 195:245-57. 2002
    ....
  13. ncbi Family history of diabetes is a major determinant of endothelial function
    Allison B Goldfine
    Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 47:2456-61. 2006
    ..We evaluated whether endothelial dysfunction was present in nondiabetic persons with a family history (FH) of diabetes and assessed its relationship with insulin resistance and atherosclerosis risk factors...